MET and non-small cell lung carcinoma: However, clinical reports regarding successful combination of EGFR and MET inhibitors in EGFR-mutated/MET-aberrant NSCLC patients are limited, and data from various clinical trials have not been uniformly conclusive, the effective therapeutic strategy remains to be determined.